NCT02151383View on ClinicalTrials.gov

Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure

PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 5, 2014

Primary Completion Date

April 3, 2017

Study Completion Date

April 3, 2017

Conditions
Acute Heart Failure
Interventions
DRUG

Serelaxin

Serelaxin was administered intravenously for up to 48 hours.

Trial Locations (10)

1211

Novartis Investigative Site, Geneva

10467

Novartis Investigative Site, The Bronx

13353

Novartis Investigative Site, Berlin

19104

Novartis Investigative Site, Philadelphia

29425

Novartis Investigative Site, Charleston

63110

Novartis Investigative Site, St Louis

79106

Novartis Investigative Site, Freiburg im Breisgau

80218

Novartis Investigative Site, Denver

80636

Novartis Investigative Site, München

WC1N 1EH

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY